Genentech, Inc.

Geralyn G DeGuzman

Thomas F Zioncheck

Rodney Gene Keck

Nishit B Modi

Brigitte M Richard

Described herein are pharmaceutical compositions including vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminal heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.

Pharmaceutical compositions including variants of vascular endothelial cell growth factor having altered pharmacological properties

Described herein are vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminus heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.

Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production

Described herein are vascular endothelial cell growth factor (VEGF) variants having structural alterations in the C-terminus heparin binding domain and methods of use. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.

Growing community of inventors

Daly City, CA, United States of America

Geralyn G DeGuzman